Aim: The lipogenic effect of pioglitazone (PGZ), an insulin (INS) sensitizer, is well established. However, few studies have evaluated PGZ effects in preventing weight loss in cancer. We investigated PGZ effects, alone or associated with INS, on INS resistance, cachexia and metabolic abnormalities induced by Walker-256 tumor in rats. , sc), were once-daily administered during 12 days, starting on the day inoculation of Walker-256 tumor cells. Rats were separated in small (about 17 g) and big (about 30 g) tumor-bearing. Key findings: Big tumor-bearing rats showed greater cachexia, blood triacylglycerol and free fatty acids and INS resistance. PGZ and PGZ + INS treatments did not change tumor growth and food intake, but reduced several abnormalities such as INS resistance, increased blood free fatty acids, retroperitoneal fat wasting and body weight loss in small tumor-bearing rats. The prevention of retroperitoneal fat wasting did not involve reduction of tumor necrosis factor-α expression increased. In big tumor-bearing rats, PGZ and PGZ + INS treatments reversed the high blood triacylglycerol and free fatty acids levels, but had no effect on other parameters. Significance: PGZ and PGZ + INS improved INS peripheral sensitivity, possibly by decreasing blood free fatty acids, and reduced fat tissue wasting and body weight loss in small tumor-bearing rats. The results suggest clinical benefits of PGZ in preventing INS resistance, adipose tissue wasting and weight loss when the tumor is small, i.e., in less severe cachexia.
Introduction
Cancer cachexia is a syndrome characterized by severe catabolism, which results in muscle and adipose tissue loss marked and consequently of body weight [1] [2] [3] . Cachexia is the main cause of morbidity and mortality in advanced cancer patients [4] , since effective clinical treatments to overcome this syndrome are not currently available.
The skeletal muscle and fat tissue wasting in cancer cachexia is caused by molecules known as mediators of cachexia, produced by tumor cells, such as proteolysis inducing factor (PIF) and lipid mobilizing factor (LMF), as well as by host tissues, such as tumor necrosis factor (TNFα), interleukin 1 (IL1) and 6 (IL6), which are capable to stimulate proteolysis and lipolysis [3, 5] .
However, it is possible that insulin (INS) resistance, often observed in patients [6] [7] [8] [9] [10] and animal models of cancer [11] [12] [13] , contributes to exacerbation of catabolic processes in muscle and fatty tissue and therefore to aggravate cachexia, since INS exerts potent anabolic and anti-catabolic effects [14] .
Accordingly, it was reported that INS resistance is present before the onset of weight loss in mice with colon-26 adenocarcinoma and rosiglitazone treatment, an INS sensitizer, improved INS sensitivity and attenuated early stages of cachexia, without changing tumor mass [11] . In addition, in later stages of cachexia, treatment with rosiglitazone attenuated fat and body mass loss in colon-26 adenocarcinoma bearing mice [15] . Although these findings [11, 15] suggest a role for INS resistance in cachexia pathogenesis, few studies have investigated the effect of INS sensitizing agents on prevention of weight loss associated with cancer.
Pioglitazone (PGZ), as the rosiglitazone, is an INS sensitizer of the class of thiazolidinediones (TZDs) used for the treatment of type 2 diabetes. The INS sensitizing effect of TZDs occurs by activation of peroxisome proliferator-activated receptor gamma (PPARγ) in adipose tissue [16, 17] . PPARγ increases the expression of genes responsible for uptake, storage and metabolism of lipids, reducing blood free fatty acids and triacylglycerol, and consequently the negative interference of free fatty acids in muscle and liver INS signaling, improving insulin signaling in these tissues [18, 19] . Free fatty acids, which are increased in cancer bearing blood [20] , impair INS signaling by decreasing the proteins phosphorylation of INS signaling pathway, such as the protein kinase B (Akt or PKB) [21] [22] [23] [24] . TZDs/PPARγ also increase INS sensitivity by reducing the release of adipokines that cause INS resistance, such as TNFα [25] and resistin [26] , and by increasing adiponectin release [27] , a known stimulator of fatty acid oxidation [18] .
In addition to the enhancement of lipids uptake and storage (lipogenesis), TZDs also stimulate the differentiation of pre-adipocytes into adipocytes (adipogenesis), causing hyperplasia and hypertrophy of adipose tissue [28] .
Thus, considering: a) the INS sensitizer, adipogenic and lipogenic effects of PGZ [28] [29] [30] [31] ; b) the INS anabolic and anti-catabolic effects [14] and c) that Walker-256 tumor-bearing rats exhibit cachexia, INS resistance and hypoglycemia [12, 13, 20, 32] , the aim of this study was to investigate the PGZ effects, isolated or associated with INS, on INS resistance, cachexia and metabolic disorders in this cancer animal model. 
Materials and methods

Drugs and chemicals
PGZ (Actos
Animals and Walker-256 tumor inoculation
Male Wistar rats (220-230 g), kept in collective boxes, 23 ± 2°C, light/dark cycle of 12 h, with free access to water and standard rodent chow (Nuvilab, CR-1 Nuvital®, Colombo, Brazil) were used in all experiments. Walker-256 carcinosarcoma cells were maintained as previously described [20, 33] . For tumor implantation, 8 × 10 7 tumor cells were suspended in phosphate buffered saline (PBS: 16.5 mM phosphate, 137 mM NaCl, 2.7 mM KCl, pH 7.4) and inoculated subcutaneously in the right flank of rats (tumor-bearing rats). Healthy rats were injected with PBS in the same place.
Treatment protocol
Walker-256 tumor-bearing rats were treated with PGZ (5.0 mg·kg − 1 , oral gavage), alone or in association with INS (NPH, 1.0 UI·kg −1 , sc), once a day (17:00 pm) for 12 days, since the day of tumor cells inoculation. Doses were based on previous study [34] . PGZ was daily dissolved in water and INS was diluted in saline (0.9% NaCl). Control rats (tumor-bearing and healthy) received vehicles. All experiments were performed on day 12 after tumor cells inoculation, 3 h after the last treatment, in fed rats. It is noteworthy that the mean survival of Walker-256 tumor-bearing rats is 13-15 days after tumor cells inoculation [35] . The experimental protocols were approved by the Ethics Committee for Animal Use of the State University of Londrina (CEUA/UEL, register number 09161). 
Insulin tolerance test (ITT)
Assessment of cachexia-anorexia parameters and tumor growth
Food intake was measured (day 11) by the difference between the amount of feed supplied and the remainder after 24 h. On day 12, rats were weighed, anesthetized with thiopental (50 mg·kg − 1 , ip) and laparotomized to collect of blood samples from the inferior vena cava to evaluate the concentrations of plasma triacylglycerol, free fatty acids and INS. Thereafter, the rats were euthanatized and the retroperitoneal and mesenteric adipose tissue were carefully removed, weighed, quickly frozen in liquid nitrogen and stored at -80°C for protein analysis. The tumor was dissected and weighed for assessment of tumor growth. The change in body mass was measured by the difference between the final body mass (day 12), discounted the tumor mass, and initial body mass (day 1).
Western blotting to assess p-Akt, total Akt, p-HSL, total HSL and TNFα
The retroperitoneal and mesenteric adipose tissues, stored at − 80°C, were homogenized in buffer (137 mM NaCl, 2.7 mM KCl, 1 mM MgCl 2 , 1 mM EDTA, 5 mM Na 4 P 2 O 7 , 10 mM NaF, Triton × 100 1%, glycerol 10%, 0.5 mM Na 3 VO 4 , 20 mM Tris, pH 7.8) containing 0.2 mM of protease inhibitors cocktails (PIC) and phenylmethylsulfonyl fluoride (PMSF). The homogenate was centrifuged (15,294 g, 40 min, 4°C) and the total proteins of the supernatant were quantified [36] . Equal amounts of total protein (80 μg) diluted in Laemmli buffer, were applied to 10% polyacrylamide gel, submitted to electrophoresis (SDS-PAGE) and transference to nitrocellulose membrane. The membranes were incubated with primary antibody (1:1000) anti-Akt (Cell Signaling®, catalog n°9272), anti-phospho-Akt Ser473 (Cell Signaling®, catalog n°9271), anti-HSL (Santa Cuz®, catalog n°sc25843), antiphospho-HSL Ser552 (Cusabio Biotech®, catalog n°csb-pa579109),
anti-TNFα (Abcam®, catalog n°ab9755) or anti-γ-tubulin (Sigma®, catalog n°T5326) overnight at 4°C, followed by incubation with secondary antibody, conjugate to peroxidase (1:5000) and finally with peroxidase substrate (ECL) for chemiluminescence detection (Amersham Image®). The density of the blots was analyzed in Image J software (National Institutes of Health, USA) and expressed in arbitrary units (AU) after normalization by constitutive protein γ-tubulin.
Assessment of secretion and insulin content in pancreatic islets
Pancreatic islets were isolated from rats by pancreas digestion with collagenase as previously described [37] . Groups of 5 islets were pre-incubated, at 37°C during 30 min, in Krebs-Henseleit (KH) with 0.2% bovine serum albumin (BSA) in 5.6 mmol·L − 1 glucose. Thereafter, islets were incubated, 37°C during 1 h, in KH with 0.2% BSA in different concentrations of glucose (5.6, 11.1 or 16.7 mM). For total INS content, islets in each well were disrupted in acid ethanol solution (1.4% chloridric acid and 74% ethanol) and sonicated (3 pulses of 5 s). At the end of the experiments, the medium was collected and INS was measured.
Biochemical analyzes
Glucose [38] , triacylglycerol [39] and free fatty acids [40] were quantified by standardized methods. INS was evaluated by radioimmunoassay [41] .
Statistical analysis
Data were tested for normal distribution (Shapiro-Wilk test) and homogeneity of variances (Brown Forsythe test) and appropriate statistical test (One-Way ANOVA followed by Newman-Keuls) were employed. Statistical analysis was carried out with the program GraphPad Prism 6.0, at a significance level of 5% (p b 0.05). Data were expressed as mean ± standard error of the mean (SEM).
Results
In most studies the rats were separated in small tumor-bearing (about 17 g) and big tumor-bearing (about 29 g), due to variation in tumors development.
Rats with small ( Fig. 1A , B) and big (Fig. 1C, D) tumors had lower KITT compared to healthy rats, indicating INS peripheral resistance in these animals. PGZ and PGZ + INS treatments improved INS peripheral response of rats with small tumor (Fig. 1B) but did not improve significantly INS peripheral response in rats with big tumor (Fig. 1D) .
Small and big tumor-bearing rats showed reduced p-Akt
Ser473
:total Akt ratio in retroperitoneal ( Fig. 2A, B ) and mesenteric fat (Fig. 2C, D) compared to healthy rats. PGZ and PGZ + INS treatments had no effect on p-Akt Ser473 :total Akt ratio in retroperitoneal and mesenteric fat in small and big tumor-bearing rats (Fig. 2) . Big tumor-bearing rats showed hypertriacylglycerolemia (Table 1) , which was reversed by PGZ and PGZ + INS treatments. In addition, small and big tumor-bearing rats showed increased plasma free fatty acids concentration compared to healthy rats (Table 1) . PGZ and PGZ + INS treatments reversed the increase in free fatty acids of small tumor-bearing rats, but only PGZ treatment reduced plasma free fatty acids in big tumor-bearing rats (Table 1) .
Walker-256 tumor growth was not affected by treatments with PGZ and PGZ + INS (Table 2) . Small tumor-bearing rats showed lower body mass gain while big tumor-bearing rats showed marked body mass loss compared to healthy rats (Table 2) . PGZ and PGZ + INS treatments increased body weight gain of small tumor-bearing rats compared to tumor-bearing rats treated with vehicle. However, PGZ and PGZ + INS treatments had no effect on body weight loss of big tumor-bearing rats (Table 2) .
Small and big tumor-bearing rats showed reduction of retroperitoneal fat, mesenteric fat, gastrocnemius muscle mass and food intake compared to healthy rats (Table 2 ). PGZ and PGZ + INS treatments prevented the loss of retroperitoneal fat in rats with small tumor, but the treatments did not show beneficial effects on other parameters affected by Walker-256 tumor (Table 2) .
Small tumor-bearing rats showed visually, but without a significant difference, increased p-HSL
Ser552
: total HSL ratio (Figs. 3A) and exhibited increased expression of TNFα (Fig. 3B) in the retroperitoneal fat, compared to healthy rats. Already, big tumor-bearing rats also showed visually increased of p-HSL Ser552 : total HSL ratio (Fig. 3C ) but did not show change in TNFα expression (Fig. 3D ) in the retroperitoneal fat compared to healthy rats. PGZ and PGZ + INS treatments had no effect on these parameters, independent of tumor size (Fig. 3) . Insulinemia of tumor-bearing rats was reduced by 80% compared to healthy rats, and PGZ and PGZ + INS treatments did not change this parameter (Fig. 4A) . INS secretion from pancreatic islets, isolated from tumor-bearing rats and incubated with 16.7 mM glucose, was reduced by 40% compared to healthy rats and was not changed by the treatments (Fig. 4B) . Intracellular INS content of islets from tumor-bearing rats was also reduced by 40% compared to healthy rats and was not improved by PGZ and PGZ + INS treatments (Fig. 4C ).
Discussion
We used the model of cachexia induced by Walker-256 tumor to test the hypothesis that pharmacological intervention with PGZ and PGZ + INS prevents INS resistance and fat and body weight loss. Our results show that PGZ and/or PGZ + INS treatments improved INS peripheral sensitivity and reduced retroperitoneal fat wasting and body weight loss in small tumor-bearing rats, without affecting tumor growth.
Although treatments with PGZ and PGZ + INS improved the INS peripheral sensitivity in small tumor-bearing rats (Fig. 1A, B) , these agents had no effect on Akt phosphorylation (p-Akt Ser473 ), the INS signaling pathway protein, which is reduced in the retroperitoneal ( Fig. 2A, B) and mesenteric (Fig. 2C, D) fat of tumor-bearing rats. However, these results do not exclude the possibility that these treatments restore the Akt phosphorylation and improve INS signaling in other tissues, including other adipose territories and muscles.
The INS sensitizing effect by TZDs is mainly attributed to the reduction of free blood fatty acids and triacylglycerol [18, 19, 28] . The products of fatty acids metabolism, such as ceramide and diacylglycerol, activate serine-threonine kinases [24] , which phosphorylate proteins of INS signaling pathway in serine residues, instead of tyrosine, decreasing the INS signal transduction [21] [22] [23] .
Confirming our previous findings [20] , big tumor-bearing rats showed increased blood free fatty acids and triacylglycerol levels. However, only fatty acids were increased in small tumor-bearing rats ( Table  1 ). The changes of these lipids were completely reversed by treatments with PGZ and PGZ + INS, except the free fatty acids levels in big tumor- (8) Values in parentheses indicate the number of animals. a p b 0.05 vs healthy (One-Way ANOVA followed by Newman-Keuls). b p b 0.01 vs healthy (One-Way ANOVA followed by Newman-Keuls). c p b 0.001 vs healthy (One-Way ANOVA followed by Newman-Keuls). d p b 0.05 vs tumor (One-Way ANOVA followed by Newman-Keuls). e p b 0.01 vs tumor (One-Way ANOVA followed by Newman-Keuls). f p b 0.001 vs tumor (One-Way ANOVA followed by Newman-Keuls).
bearing rats that was not reversed by PGZ + INS treatment (Table 1) . TZDs decrease blood free fatty acids and triacylglycerol by different mechanisms including: increased expression of genes related to uptake, oxidation and storage of lipids in adipose tissue, such as lipoprotein lipase, AP2 and acetyl-CoA synthetase [42] [43] [44] ; increased adiponectin release, which stimulates uptake, oxidation and storage of lipids in the liver [27, 28] , and increased AMP:ATP ratio, by inhibition of complex I of respiratory chain [45] , which activates 5′ AMP-activated protein kinase (AMPK) and stimulates ATP generating pathways, such as the fatty acids oxidation [46, 47] . The decreased blood fatty acids level by treatments with PGZ and PGZ + INS in small tumor-bearing rats is consistent with the improvement in INS peripheral sensitivity (Fig. 1) . However, in big tumor-bearing rats the lack of PGZ effect, which also decreased blood free fatty Table 2 Tumor mass, initial weight, final weight, change of body mass, retroperitoneal fat mass, mesenteric fat mass, gastrocnemius muscle mass and food intake of fed healthy and Walker-256 tumor-bearing rats (small tumor and big tumor) treated with pioglitazone (Tumor + PGZ), pioglitazone plus insulin (Tumor + PGZ + INS) or vehicle during 12 days. 16.14 ± 0.98 (20) 28.88 ± 0.62 (16) 28.52 ± 0.99 (14) 32.10 ± 1.64 (15) Initial weight (g) 229.40 ± 5.22 (18) 231.60 ± 4.22 (20) 231.60 ± 3.33 (19) 230.00 ± 2.83 (20) 231.88 ± 5.24 (17) 234.86 ± 4.57 (14) 233.00 ± 3.45 acids, on INS peripheral response could be a consequence of the increased levels of others factors that cause INS resistance, due to larger tumor size. It is noteworthy that big tumor-bearing rats showed greater INS resistance (Fig. 1) , blood triacylglycerol and free fatty acids levels (Table 1 ) and cachexia ( Table 2) .
In agreement with the improvement of INS peripheral sensitivity, treatment with PGZ and PGZ + INS prevented body weight loss by 25% and 28%, respectively, in small tumor-bearing rats, an effect that was accompanied by prevention of retroperitoneal fat loss but not of mesenteric fat and gastrocnemius muscle loss (Table 2 ). In contrast, no beneficial effect of the treatments was observed in big tumor-bearing rats. It is possible that prevention of body mass loss of small tumorbearing rats involved the action of PGZ in other fat deposits, since TZDs have different effects in distinct adipose territories. TZDs stimulate the differentiation of pre-adipocytes into adipocytes and increase the uptake of free fatty acids, promoting hypertrophy and hyperplasia of adipose tissue [28] , effects that are more prominent in subcutaneous than in visceral fat [29, 30] . In subcutaneous fat, TZDs increase the expression of adipocyte protein 2 (AP2) and diacylglycerol acetyltransferase-1 (DGTA-1), promoting adipogenesis and synthesis of triacylglycerol [30, 31] . In contrast, in visceral fat the TZDs promote lipolysis by increasing the expression of carnitine palmitoyltransferase-1 (CPT1), coactivator of PPARγ 1α (PGC-1α) and mitochondrial-1 uncoupling protein (UCP-1) genes, key cofactors in thermogenesis [30, 48] . Thus, PPARγ activation promotes remodeling of adipose tissue, inducing cellular proliferation and hypertrophy in the subcutaneous fat and stimulating lipolysis and thermogenesis in visceral fat. Therefore, prevention of body weight loss in small tumor-bearing rats treated with PGZ and PGZ + INS is also possibly a result of the effects of these treatments on the subcutaneous fat.
The prevention of body weight and retroperitoneal fat loss of small tumor-bearing rats by treatments did not involve improvement of the food intake or reduction of tumor growth ( Table 2 ). The lack of effect of treatments on tumor growth corroborates studies with Walker-256 tumor [49] and other tumor types [11, 15, 50, 51] . The prevention of body weight and retroperitoneal fat loss of small tumor-bearing rats by PGZ and PGZ + INS also did not involve reduction of TNFα expression, which is increased in this tissue. In turn, p-HSL: total HSL values, visually increased in tumor-bearing rats, were similar to those of healthy rats, when the tumor-bearing rats were treated with PGZ or PGZ + INS (Fig. 3) . The increase in TNFα expression in retroperitoneal fat of tumor-bearing rats corroborates with the fat mass depletion. It is known that TNFα stimulates lipolytic enzymes such as HSL [52] .
According to other studies, tumor-bearing rats showed hipoinsulinemia [32] (Fig. 4A) , which is probably consequence of decreased INS secretion (Fig. 4B) and synthesis (Fig. 4C ) by pancreatic-β cells. Treatments with PGZ and PGZ + INS did not improve the secretory dysfunction and decreased INS synthesis of the islet and nor hypoinsulinemia, and this may have contributed, together with increased levels of cachexia mediators (LMF, PIF, TNFα, IL1, IL6), induced by disease evolution, to decreased therapeutic effects of treatments.
Conclusion
PGZ and PGZ + INS treatments improved INS peripheral sensitivity and reduced fat wasting and body weight loss in small tumor-bearing rats, but not big ones. Taken together, the results suggest clinical benefits of PGZ in preventing INS resistance, fat wasting and weight loss when the tumor is small, i.e., in less severe cachexia. 
